ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Sep 17th, 2020 - Amyotrophic lateral sclerosis (ALS) has a reported incidence of 1-2/100,000 person-years. It is estimated that there are 5000 people with ALS in the UK at any one time; however, the true figure and geographical distribution, are unknown. In this s...

Sep 17th, 2020 - Brain-computer interface (BCI) technology to assist with mobility and communication is an active area of research in amyotrophic lateral sclerosis (ALS). Implantable BCI offers promise for individuals with severe disease, such as locked-in syndrom...

Sep 17th, 2020 - Heavy metals are considered to be among the leading environmental factors that trigger amyotrophic lateral sclerosis (ALS). However, no convincing biopathological mechanism and therapeutic clinical implication of such metals in ALS pathogenesis ha...

Sep 16th, 2020 - The 'split hand' sign refers to preferential wasting of the thenar and first dorsal interosseous muscles with relatively sparing of the hypothenar muscles in amyotrophic lateral sclerosis (ALS) and both cortical and spinal/peripheral excitotoxic m...

Sep 16th, 2020 - To describe some current models of outpatient neuropalliative care available to patients with amyotrophic lateral sclerosis at different institutions within the United States. Six neuropalliative care physicians were asked to contribute written de...

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-act...

Jan 8th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

Dec 31st, 2015 - In 2013, MDA launched the U. S.

Sep 14th, 2011 - The evidence base for the diagnosis and management of amyotrophic lateral sclerosis (ALS) is weak. To provide evidence-based or expert recommendations for the diagnosis and management of ALS based on a literature search and the consensus of an exp...

Oct 13th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

Sep 17th, 2020 - Amyotrophic lateral sclerosis (ALS) has a reported incidence of 1-2/100,000 person-years. It is estimated that there are 5000 people with ALS in the UK at any one time; however, the true figure and geographical distribution, are unknown. In this s...

Sep 17th, 2020 - Brain-computer interface (BCI) technology to assist with mobility and communication is an active area of research in amyotrophic lateral sclerosis (ALS). Implantable BCI offers promise for individuals with severe disease, such as locked-in syndrom...

Sep 17th, 2020 - Heavy metals are considered to be among the leading environmental factors that trigger amyotrophic lateral sclerosis (ALS). However, no convincing biopathological mechanism and therapeutic clinical implication of such metals in ALS pathogenesis ha...

Sep 16th, 2020 - The 'split hand' sign refers to preferential wasting of the thenar and first dorsal interosseous muscles with relatively sparing of the hypothenar muscles in amyotrophic lateral sclerosis (ALS) and both cortical and spinal/peripheral excitotoxic m...

Sep 16th, 2020 - To describe some current models of outpatient neuropalliative care available to patients with amyotrophic lateral sclerosis at different institutions within the United States. Six neuropalliative care physicians were asked to contribute written de...

Jun 24th, 2020 - TEL AVIV (Reuters) - BrainStorm Cell Therapeutics Inc said on Wednesday it will begin a clinical trial of its experimental stem cell treatment in patients with Alzheimer’s disease. The U.S.-Israeli company is already conducting advanced trials of ...

Dec 17th, 2019 - (Reuters) - Privately held drug developer Amylyx Pharmaceuticals Inc said on Tuesday its experimental therapy to treat amyotrophic lateral sclerosis (ALS) helped slow the progression of the fatal neurological disorder in a mid-stage study. ALS, al...

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-act...

Nov 22nd, 2019 - (Reuters) - The U.S. Food and Drug Administration on Friday approved bit.ly/2pIFzi5 Aquestive Therapeutics' treatment for neurological disorder amyotrophic lateral sclerosis (ALS). Shares of the company, which developed riluzole oral film (ROF) an...

Oct 19th, 2019 - AUSTIN – Lack of upper motor neuron signs on examination, presence of sensory symptoms, and absence of tongue fasciculations are common causes of amyotrophic lateral sclerosis (ALS) misdiagnosis, according to an investigation presented at the annu.